靶向P-钙黏蛋白的放射免疫偶联物111In或90Y-FF-21101的临床前表征
本研究在临床前评价了抗P-钙黏蛋白单克隆抗体FF-21101标记111In或90Y后的放射化学纯度、亲和力、稳定性、小鼠药代动力学与抑瘤效果,并用食蟹猴γ相机图像估算人体吸收剂量。结果显示标记物稳定、肿瘤摄取与P-钙黏蛋白表达强度相关,90Y-FF-21101单次静脉注射可显著抑制肿瘤生长,猴药代动力学外推提示其具有临床转化潜力。
要点
- 111In-与90Y-FF-21101放射化学纯度分别达98.2%±2.5%与99.3%±0.6%,人血清中96小时稳定。
- 111In-FF-21101肿瘤摄取与肿瘤细胞P-钙黏蛋白表达强度密切相关。
- 90Y-FF-21101单次静脉给药可显著抑制NCI-H1373与EBC-1移植瘤生长。
核心结论
- FF-21101放射免疫治疗在小鼠移植瘤模型中表现出高抗肿瘤亲和力与抗肿瘤疗效。
- 猴药代动力学外推至人体提示FF-21101治疗P-钙黏蛋白表达肿瘤具有临床应用潜力。
研究设计与样本
- 研究为临床前药代动力学与药理学评价,包括放射化学纯度、结合亲和力与人血清稳定性检测。
- 在正常小鼠比较111In或90Y-FF-21101药代动力学,在高、中、无P-钙黏蛋白表达的小鼠皮下移植瘤模型研究肿瘤摄取与抑瘤效果。
- 利用食蟹猴γ相机图像估算90Y-FF-21101的人体吸收辐射剂量。
主要发现
- 111In-与90Y-FF-21101放射化学纯度分别为98.2%±2.5%(n=9)与99.3%±0.6%(n=5)。
- 111In-FF-21101与90Y-FF-21101的解离常数分别为1.083 nM与1.367 nM。
- 111In-与90Y-FF-21101在人血清中孵育96小时后稳定,在正常小鼠中展现相似药代动力学。
- 111In-FF-21101肿瘤摄取与细胞P-钙黏蛋白表达强度密切相关。
- 90Y-FF-21101每只动物静脉注射3.7 MBq(NCI-H1373)与7.4 MBq(EBC-1)后未观察到肿瘤复发。
关键数值与推荐
- 基于疗效与安全性,人体适宜抗体剂量考虑为4.8 mg/m2。
- 90Y-FF-21101最大耐受给药活度估计为2,886 MBq/人。
- 小鼠移植瘤模型中肿瘤摄取与猴脾脏估算吸收剂量随111In-FF-21101抗体剂量增加而降低。
- 猴红骨髓估算吸收剂量随抗体剂量增加而升高。
临床怎么用
- 临床前数据支持FF-21101作为P-钙黏蛋白表达肿瘤放射免疫治疗的候选药物进一步开展临床研究。
- 抗体剂量可能影响肿瘤摄取与脾脏、红骨髓吸收剂量,临床转化时需关注剂量选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
P-cadherin is overexpressed in various cancers and can be a target for radioimmunotherapy. We investigated the preclinical pharmacokinetics and pharmacology of FF-21101, an 111In- or 90Y-conjugated monoclonal antibody against P-cadherin, to evaluate its clinical applications. Methods: The radiochemical purity, binding affinity, and in vitro serum stability of 111In or 90Y-labeled FF-21101 were evaluated. The pharmacokinetics of 111In or 90Y-FF-21101 were compared in normal mice. Tumor accumulation after 111In-FF-21101 administration was investigated in mice bearing subcutaneous tumors with high (NCI-H1373), moderate (EBC-1), or no (A549) P-cadherin expression. The tumor suppression effect after a single intravenous injection of 90Y-FF-21101 was assessed in NCI-H1373 and EBC-1 mouse xenograft models. The relationship between antibody dose and tumor accumulation was investigated in the NCI-H1373 mouse xenograft model. The absorbed radiation dose in humans after injection of 90Y-FF-21101 was estimated using γ-camera images of cynomolgus monkeys. Results: The radiochemical purities of 111In- and 90Y-FF-21101 were 98.2% ± 2.5% (n = 9) and 99.3% ± 0.6% (n = 5), respectively. The dissociation constants were 1.083 nM for 111In-FF-21101 and 1.367 nM for 90Y-FF-21101. Both 111In- and 90Y-FF-21101 were stable in human serum after 96 h of incubation and exhibited similar pharmacokinetics in normal mice. The tumor accumulation of 111In-FF-21101 was closely related to the intensity of P-cadherin expression in the cells. 90Y-FF-21101 showed significant tumor growth inhibition, indicating that NCI-H1373 and EBC-1 recurrence was not observed after intravenous administration of 3.7 and 7.4 MBq, respectively of 90Y-FF-21101 per animal. Tumor uptake in the mouse xenograft model and estimated absorbed radiation doses in the spleen of monkeys decreased with increasing antibody doses of 111In-FF-21101. Conversely, the estimated absorbed radiation dose in the red marrow increased with increasing antibody dose. An antibody dose of 4.8 mg/m2 was considered appropriate for humans, on the basis of efficacy and safety. The maximum tolerated administered activity of 90Y-FF-21101 was estimated to be 2,886 MBq/human. Conclusion: FF-21101 radioimmunotherapy exhibited high antitumor affinity and antitumor efficacy in mouse xenograft models. Extrapolation of the pharmacokinetics in monkeys to humans suggests the potential for clinical application of FF-21101 for treating P-cadherin-expressing tumor.
引用
- Funase Y, Nakamura E, Kajita M, et al. Preclinical Characterization of the Radioimmunoconjugate 111In or 90Y-FF-21101 Against a P-Cadherin-Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate. J Nucl Med. 2020. PMID: 32737245. doi:10.2967/jnumed.120.245837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。